Thomas H. Kramer
Prior to practicing law, Tom was a pharmacologist, specializing in neuropharmacology, anesthesiology, and pain management while a member of the faculty of the Department of Anesthesia at the University of Pennsylvania. He has published extensively in the scientific literature and received grant funding from the National Institute on Drug Abuse/NIH. Tom is also a registered pharmacist with extensive practice experience.
Delaware; Pennsylvania (pending); US Patent and Trademark Office: Attorney and Agent
While attending law school, Tom served as a judicial extern to the Honorable Leonard P. Stark, U.S. District Court, District of Delaware.
Juris Doctor – Cum Laude May 2015
Delaware Law School, Widener University, Wilmington, DE
Postdoctoral Fellowship—Pharmacology 1988 – 1989
Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ
Postdoctoral Fellowship—Clinical Pharmacy 1987
Department of Pharmacy Practice, College of Pharmacy, The University of Arizona, Tucson, AZ
Doctor of Pharmacy 1986
College of Pharmacy, The University of Arizona, Tucson, AZ
Kramer, TH, Proposed Legislative Solutions to the Nonpracticing Entity Patent Assertion Problem: The Risks for Biotechnology and Pharmaceuticals, 39 Del J Corp Law 467 (2014).
Kramer, TH, Appraisal “Arbitrage”: Give It Another Name, But Let It Continue, Del J Corp L (Mar. 8, 2015), www.djcl.org/blog.
Kramer TH. Opioids in Anesthesia Practice. In Longnecker DE, Murphy FL, eds.: Introduction to Anesthesia, 9th ed. Philadelphia: WB Saunders, 1997, pp 99-109.
Kramer TH, Bartosz-Bechowski H, Davis P, Hruby VJ, Porreca F. Extraordinary potency of a novel delta opioid receptor agonist is due in part to increased efficacy. Life Sci. 1997;61(2):129-35.
Cork RC, Kramer TH, Dreischmeier B, Behr S, DiNardo JA. The effect of esmolol given during cardiopulmonary bypass. Anesth Analg. 1995 Jan;80(1):28-40.
Kramer TH, Davis P, Hruby VJ, Burks TF, Porreca F. In vitro potency, affinity and agonist efficacy of highly selective delta opioid receptor ligands. J Pharmacol Exp Ther. 1993 Aug;266(2):577-84.
Kramer TH, Gaar GG, Ray CG, Minnich L, Copeland JG, Connor JD. Hemodialysis clearance of intravenously administered ribavirin. Antimicrob Agents Chemother. 1990 Mar;34(3):489-90.
Kramer TH, Ayres EA, Burks TF. In vivo concentration-response relationships for fentanyl: absence of acute tolerance in the rat tail-flick test. NIDA Res Monogr. 1990;105:558-9.
Kramer TH, Toth G, Ayres EA, Hruby VJ, Burks TF. Antinociceptive actions of novel delta opioid receptor agonists in the mouse. Prog Clin Biol Res. 1990;328:473-6.
Kramer TH, Cork RC, Gandolfi AJ. Pharmacokinetics of sufentanil. Can J Anaesth. 1989 Jul;36(4):485-6.
Kramer TH, Shook JE, Kazmierski W, Ayres EA, Wire WS, Hruby VJ, Burks TF. Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J Pharmacol Exp Ther. 1989 May;249(2):544-51.
Burks TF, Kramer TH, Davis P, Toth G, Hruby VJ. Novel [D-Pen2, D-Pen5]enkephalin derivatives with increased delta receptor potency and selectivity: potential tools for opioid pharmacology. NIDA Res Monogr. 1989;95:291-2.
Kramer TH, Ayres EA, Burks TF. Evidence for rapid development and loss of opioid tolerance to fentanyl in the rat. NIDA Res Monogr. 1989;95:310-1.
Plezia PM, Kramer TH, Linford J, Hameroff SR. Transdermal fentanyl: pharmacokinetics and preliminary clinical evaluation. Pharmacotherapy. 1989;9(1):2-9.